Drugs / VS-5584
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02372227 | Jan → Oct 2015 | malignant mesothelioma | Verastem, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01991938 | Nov 2013 → Dec 2016 | lymphoma, metastatic malignant neoplasm | Verastem, Inc. | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2015-04-22 | Verastem, Inc. | Results Verastem Presents Encouraging Scientific Data on the Preferential Targeting of Cancer Stem Cells at the 2015 American Association of Cancer Research Annual Meeting verastem.com ↗
The data presented provide continued evidence that VS-6063, VS-4718 and VS-5584 effectively target cancer stem cells, reduce tumor initiating capability and prolong the anti-tumor response to standard of care chemotherapy in preclinical models of multiple tumor types. |
| 2015-02-12 | Verastem, Inc. | Regulatory Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma verastem.com ↗
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma. |
| 2015-01-20 | Verastem, Inc. | Regulatory Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma verastem.com ↗
today announced that VS-5584 has received orphan medicinal product designation from the European Commission for use in mesothelioma. |
| 2015-01-16 | Verastem, Inc. | Results Verastem Announces Publication of Scientific Data for VS-5584 in Cancer Research verastem.com ↗
The paper discusses results from preclinical research evaluating VS-5584, a highly potent, selective small molecule inhibitor of mTORC1/2 and Class I PI3K kinases, which preferentially targets cancer stem cells (CSCs) in vitro and in vivo . |
| 2014-11-21 | Verastem, Inc. | Results Verastem Presents Data at the 2014 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics verastem.com ↗
The encouraging data reported here from the combination of VS‐6063 and VS‐5584 in pre-clinical models of mesothelioma offers a novel therapeutic approach in this setting. |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS-5584 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02372227 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3393066 ↗1“VS-5584, a PI3K/mTOR kinase inhibitor” NCT01991938 ↗ |
| Modality | Small molecule | — CHEMBL3393066 ↗ |
| Route | Oral | “Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle” NCT01991938 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3393066 ↗ |